Capabilities

Agreement to acquire Corthera Inc.

Novartis

Our attorneys represented Novartis in its agreement to acquire Corthera Inc. Novartis will gain exclusive worldwide rights to relaxin, a recombinant version of a naturally occurring human peptide, through the acquisition of the privately held US biopharmaceutical company Corthera Inc. Relaxin is currently in Phase III clinical trials as a potential treatment option for patients with acute decompensated heart failure (ADHF).

Email Disclaimer